Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 3Phase 1 2Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Lymphoid 1

Conditions

Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Recurrence 3Hematologic Neoplasms 3Melanoma 2Lymphoma, Non-Hodgkin 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Solid Tumors Harboring NTRK Fusion 1Skin Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neuroblastoma 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Multiple Myeloma 1Mesothelioma, Malignant 1Mastocytosis, Systemic 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1Lung Neoplasms 1Locally Advanced Solid Tumors 1Leukemia, Myeloid, Acute 1Leukemia, Mast-Cell 1Head and Neck Neoplasms 1Glioma 1Gastrointestinal Stromal Tumors 1Endometrial Neoplasms 1Diffuse Intrinsic Pontine Glioma 1

Interventions

nilotinib 2asciminib 1Imatinib Mesylate 1Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Has announcements × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Clear all
NCT02081378 2024-03-18

A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL

Novartis

Phase 1 Completed
326 enrolled 1 FDA
MyeloidOther hematologic neoplasm

Recurrence, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01077544 2020-12-29

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

Novartis

Phase 1 Completed
15 enrolled 20 charts 1 FDA
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡